Tue, 20 Oct 2026
04:57:30 pm
Rudransh Sangwan
Published at: October 15, 2026, 7:29 AM
Synopsis
IDBI Bank shares decline as the Fairfax deal gets Cabinet approval. Explore the latest share price, privatisation developments and what investors should watch next.

IDBI Bank shares fell over 7% on October 15, 2026, after rising nearly 13% in the previous session. The earlier rally followed Cabinet approval of Fairfax Financial Holdings’ proposed acquisition of a 60.72% stake in the bank.
The ₹52,878 crore deal marks a major step in IDBI Bank’s privatisation. Investors are now watching the next steps in the transaction and the bank’s financial performance.
IDBI Bank shares fell to ₹83.87 on October 15, compared with the previous session’s high of ₹93.60.
| Market Detail | Figure |
|---|---|
| Share price on October 15 | ₹83.87 |
| Intraday decline | Over 7% |
| Previous session’s rally | Nearly 13% |
| Proposed deal value | ₹52,878.08 crore |
The fall came after the stock’s sharp rally in the previous session. Investors appeared to book profits following the positive news about the Fairfax deal.
Profit-booking happens when investors sell shares to secure gains after a price rise. However, the available information does not confirm whether this was the only reason for the decline.
The Union Cabinet approved the proposed sale of a combined government and LIC stake in IDBI Bank to a Fairfax subsidiary.
| Deal Detail | Information |
|---|---|
| Proposed buyer | Fairfax Financial Holdings’ subsidiary |
| Stake being acquired | 60.72% |
| Deal value | ₹52,878.08 crore |
| Fairfax bid price | ₹81 per share |
| Average fair valuation | ₹75.99 per share |
| Government’s expected remaining stake | 15% |
| LIC’s expected remaining stake | 19% |
The deal still requires regulatory clearances, including the RBI’s fit-and-proper assessment, before completion.
IDBI Bank has improved its asset quality and profitability in recent years.
Its gross NPA ratio fell from 31.78% in September 2018 to 2.32% in March 2026. Its net NPA ratio declined from 17.30% to 0.15% over the same period.
| Financial Metric | Reported Figure |
|---|---|
| FY26 net profit | ₹9,513 crore |
| Total business | ₹6.27 lakh crore |
| Deposits | ₹3.56 lakh crore |
| Net advances | ₹2.72 lakh crore |
| Year-on-year total business growth | 18% |
Total business and deposit figures are reported as of September 30, where applicable.
Investors should track:
IDBI Bank shares fell over 7% after a nearly 13% rally, as investors appeared to book profits following Cabinet approval of Fairfax’s proposed ₹52,878 crore acquisition.
The bank’s improving financial performance and the proposed ownership change remain important developments. However, the deal is still subject to regulatory approvals, and the stock’s future performance will depend on several factors.
The shares fell over 7% after a nearly 13% rally in the previous session. Profit-booking was reported as a possible reason.
The proposed transaction is valued at ₹52,878.08 crore for a 60.72% stake.
No. The transaction remains subject to required regulatory approvals.
Its gross NPA ratio fell to 2.32% in March 2026 from 31.78% in September 2018.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

L&T has begun preliminary work on the New Tashkent International Airport project after receiving a limited notice to proceed.

DLF share price has 41% upside, according to HSBC’s target. Compare Jefferies, CLSA and other broker views on sales, cash flow and valuations.

Divi's Laboratories shares rose 1.01% to Rs 9,242.50 after a positive EU opinion on Eli Lilly's weight loss drug Foundayo. See the growth outlook.

Awfis revenue target exceeds Rs 1,800 crore for FY27, with flexible workspace demand supporting growth. Expansion and execution remain key to watch.

L&T has won a contract worth over Rs 15,000 crore. The client, project scope and execution timeline remain undisclosed, leaving its revenue impact...